On March 6, 2018, the US Food and Drug Administration (FDA) authorized 23andMe's direct-to-consumer (DTC) test that provides information on 3 BRCA1/BRCA2 gene mutations by analyzing DNA from a consumer's self-collected saliva sample.
INTRODUCTION
On March 6, 2018, the US Food and Drug Administration (FDA) authorized 23andMe's direct-to-consumer (DTC) test that provides information on 3 BRCA1/BRCA2 gene mutations by analyzing DNA from a consumer's self-collected saliva sample. 1 This is the first FDA-authorized DTC test that detects the genetic risk of developing breast and ovarian cancer in women and breast and prostate cancer in men. Its authorization signals the FDA's significant progress in establishing a sensible approach to regulating DTC genetic health risk (GHR) tests that aims to balance consumers' access to innovative technologies with the need to ensure analytical and clinical validity. An easing regulatory environment and burgeoning consumer interest are estimated to triple the market for DTC genetic testing from approximately $99 million in 2017 to $310 million in 2022 with 25% annual growth. 2 At the same time, however, challenging regulatory, social, and ethical questions remain.
SIGNIFICANCE OF THE FDA'S DECISION
Federal lawmakers and regulators, including the FDA, have been concerned about DTC genetic tests since they first reached the US market in the 2000s (Table 1) . In 2013, this concern came to a head when the FDA sent a warning letter to 23andMe instructing it to discontinue marketing its DTC tests for BRCA gene mutations, among others, until it received the FDA's authorization. 3 Since then, 23andMe has gradually received the FDA's authorization to market various tests that report health-related information as the FDA's approach to regulating DTC genetic tests has evolved (Table 1) .
Most recently, the FDA authorized 23andMe's BRCA test through the de novo classification process for novel medical devices. 4 When the FDA authorized the test, it also established special controls intended to address risks that the test results will be misunderstood, incorrect, or incorrectly interpreted. 1 These include requiring that the labeling and 23andMe's website provide certain basic information about the test, warning statements, descriptions of the limitations of the test, and technical information about the test's performance characteristics to help consumers to understand the import of positive and negative results. 1 The FDA's decision denotes that there is a viable path forward for marketing DTC tests for genetic cancer risks: the agency is willing to authorize such tests with regulatory controls that increase the likelihood that the tests' benefits will outweigh their risks. This evolution in the FDA's approach to DTC tests for genetic cancer risks may have live-saving benefits for consumers. Although the 3 variants included in the 23andMe test account for a small percentage of all hereditary cancers and are most commonly found in individuals of Ashkenazi Jewish descent, women with these variants have a 45% to 85% chance of developing breast cancer and a 44% chance of developing ovarian cancer by the age of 70 years. 5 If used and interpreted appropriately, 23andMe's test could be a powerful tool for cancer prevention for this group of womennot just for one individual but for an entire family. More broadly, if developed, DTC tests for genetic variants associated with cancer risks that are common in other populations, such as African American and Hispanic women, who are 4 to 5 times less likely than women of Western European descent to undergo BRCA screening despite facing similar mutation rates, 6 could be game changers in democratizing access to such information.
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CONCERNS GOING FORWARD The FDA's authorization of 23andMe's BRCA test, however, does not mark an end to regulatory, social, and ethical issues associated with such tests. For the FDA, it is critical to monitor how consumers use and respond to GHR information. Although 23andMe provided the FDA data on the test's accuracy and reproducibility as well as user comprehension studies, other evidence suggests that consumers do not fully understand the results of GHR tests. 7 There are concerns over the possible psychological implications of taking the test in the absence of a genetic counselor's advice and support. Moreover, as the test results are an incomplete picture of a person's cancer risk, the FDA has warned that consumers should not use the test results as a basis for any medical decisions, including initiating antihormone therapies and prophylactically removing breasts or ovaries. 1 If evidence emerges that test results are misunderstood or misused in one of these ways, the FDA may need to adjust its regulatory approach.
There are also regulatory considerations associated with access to genetic information beyond those within the FDA's jurisdiction, such as concerns about discrimination against individuals with known GHRs. As another example, the privacy protections provided by the Health Insurance Portability and Accountability Act apply only to certain entities, such as health plans and health care providers who electronically transmit specific information. 8 Because DTC testing companies are not likely to be entities required to comply with the Health Insurance Portability and Accountability Act, new regulatory strategies may be needed to protect information associated with DTC GHR testing, which consumers may perceive to be highly sensitive.
Another area of particular importance is the relationship between specialized professionals, consumers, and GHR test companies. 
2006
• The GAO launches an investigation and issues a report that raises concerns about whether DTC tests mislead consumers.
• The FTC, the FDA, and the CDC issue an alert cautioning consumers about misleading DTC tests. 2007
• 23andMe launches. 2010
• The Secretary's Advisory Committee on Genetics, Health, and Society issues a report on DTC genetic testing identifying concerns about "the ability of consumers to make informed decisions about DTC genetic testing services." • The GAO issues a second report on DTC genetic tests in which it identifies deceptive marketing practices and observes that results are misleading or of little practical use.
• The FDA issues letters to numerous DTC testing companies, including 23andMe, explaining that their products appear to be devices that require premarket review. 2012
• 23andMe submits 510(k)s for several of the health-related uses of its DTC genetic test. 2013
• After 23andMe fails to address questions about its 510(k)s and launches a new marketing campaign, the FDA issues a warning letter to the company asserting that the company's health-related DTC genetic tests are unauthorized devices, directing the company to stop marketing the tests, and effectively removing health-related DTC genetic tests from the US market. The FDA notes that a false-positive result from the BRCA test in particular might lead a consumer to undergo unnecessary morbidity-inducing treatments, whereas a false-negative might falsely reassure consumers and thereby reduce the chances that they would pursue the best tests and health practices in the future. 2015
• In February, the FDA authorizes the marketing of 23andMe's DTC carrier screen for Bloom syndrome.
• In October, the FDA announces its intent to exempt from premarket notification requirements many DTC autosomal recessive carrier screens, and 23andMe begins marketing additional carrier screens. 2017
• In April, the FDA authorizes 23andMe's reports on a consumer's genetic health risk, rather than carrier status, for 10 conditions, including rare illnesses such as factor XI deficiency, Gaucher disease type 1, and celiac disease, as well as, if the consumer chooses, Alzheimer disease and Parkinson disease.
• In November, the FDA finalizes its proposal for regulating DTC autosomal recessive career screens and announces its intent to implement a "streamlined" path to market for genetic health risk tests. Under the proposed approach, a manufacturer would undergo a 1-time review, after which it could add to its DTC test certain genetic health risk reports without undergoing premarket review. This approach, however, may not apply to, among others, cancer risk tests in which the "result may lead to prophylactic screening, confirmatory procedures, or treatments that may incur morbidity or mortality to the patient." 2018
• The FDA authorizes the 23andMe DTC test that provides information on 3 BRCA1/BRCA2 breast cancer gene mutations. support is entirely lacking when an individual takes a test at home. If it is within their expertise, genetic counselors and other medical professionals who counsel patients about genetic testing may also be able to help consumers protect their privacy and autonomy by aiding consumers in understanding the nature of DTC tests and the company's policy on how consumers' data or samples will be stored, used, or sold (or at least alerting consumers that such policies should be carefully read). Although consumers typically sign an agreement allowing the company to retain and use their data, they may not understand that the company can sell information to third parties without their awareness, nor do agreements necessarily conform to standards for informed consent in a medical setting. On the other hand, involving professionals may make GHR information less accessible and undermine some of the potential benefits of DTC testing.
Wider access to GHR information may also highlight questions of genetic responsibility, which refers to consumers' responsibility to acquire genetic knowledge and share relevant results with their families and to medical professionals' responsibility to disclose relevant genetic information to patients' families or encourage patients to share their genetic information. Consistent with the value placed on confidentiality in US ethical and legal standards, most US medical associations agree that medical professionals have a duty to advise patients of the relevance of genetic information to their relatives and of the importance of sharing such information, but they do not have a duty to breach patient confidentiality and warn relatives directly. 9 Patients may have strong reasons not to share genetic information with relatives, including estranged relationships, uncertainty about whether relatives want to be informed, concerns about personal safety, and cultural values. 10 In contrast, extending the principles of the oft cited Tarasoff case, in which a California court ruled that mental health professionals have a duty to protect third parties threatened with bodily harm in certain circumstances, 11 others argue that patients and medical professionals have a moral or even legal duty to share important genetic information with relatives.
CONCLUSION
The FDA's authorization of 23andMe's BRCA test marks an evolution in the agency's approach to overseeing DTC genetic testing, whose market is expected to keep booming. Although 23andMe's BRCA test specifically has significant limitations, this regulatory shift has the potential to increase access to beneficial innovative devices while also providing assurance of safety and effectiveness. However, concerns persist about the implications of DTC testing becoming more widely available. It will be critical for regulators, consumers, and the medical community to think through important remaining regulatory, social, and ethical questions to help to ensure that consumer autonomy, privacy, confidentiality, and health are appropriately protected.
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